Concentration-Dependent Pro- and Antitumor Activities of Quercetin in Human Melanoma Spheroids: Comparative Analysis of 2D and 3D Cell Culture Models.


Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
30 Jan 2021
Historique:
received: 23 12 2020
revised: 25 01 2021
accepted: 27 01 2021
entrez: 12 2 2021
pubmed: 13 2 2021
medline: 10 4 2021
Statut: epublish

Résumé

Quercetin, a dietary flavonoid found in fruits and vegetables, has been described as a substance with many anti-cancer properties in a variety of preclinical investigations. In the present study, we demonstrate that 2D and 3D melanoma models exhibit not only different sensitivities to quercetin, but also opposite, cancer-promoting effects when metastatic melanoma spheroids are treated with quercetin. Higher concentrations of quercetin reduce melanoma growth in three tested cell lines, whereas low concentrations induce the opposite effect in metastatic melanoma spheroids but not in the non-metastatic cell line. High (>12.5 µM) or low (<6.3 µM) quercetin concentrations decrease or enhance cell viability, spheroid size, and cell proliferation, respectively. Additionally, melanoma cells cultivated in 2D already show significant caspase 3 activity at very low concentrations (>0.4 µM), whereas in 3D spheroids apoptotic cells, caspase 3 activity can only be detected in concentrations ≥12.5 µM. Further, we show that the tumor promoting or repressing effect in the 3D metastatic melanoma spheroids are likely to be elicited by a precisely controlled regulation of Nrf2/ARE-mediated cytoprotective genes, as well as ERK and NF-κB phosphorylation. According to the results obtained here, further studies are needed to better characterize the mechanisms of action underlying the pro- and anti-carcinogenic effects of quercetin on human melanomas.

Identifiants

pubmed: 33573155
pii: molecules26030717
doi: 10.3390/molecules26030717
pmc: PMC7866537
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
NF-E2-Related Factor 2 0
NF-kappa B 0
NFE2L2 protein, human 0
Quercetin 9IKM0I5T1E
Carboxylic Ester Hydrolases EC 3.1.1.-
arylesterase EC 3.1.1.2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Österreichische Forschungsförderungsgesellschaft
ID : 853951
Organisme : NÖ Forschungs- und Bildungsges.m.b.H.
ID : LSC14-007

Références

Hepatology. 2010 Jun;51(6):2183-92
pubmed: 20513003
Ann Oncol. 2011 Feb;22(2):438-43
pubmed: 20688844
Front Nutr. 2016 Oct 31;3:48
pubmed: 27843913
Eur J Clin Pharmacol. 1975 Dec 19;9(2-3):229-34
pubmed: 1233267
Altern Med Rev. 2000 Jun;5(3):196-208
pubmed: 10869101
Am J Cancer Res. 2019 Aug 01;9(8):1517-1535
pubmed: 31497340
Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):684-93
pubmed: 17416758
MMWR Morb Mortal Wkly Rep. 2015 Jun 5;64(21):591-6
pubmed: 26042651
Nutr Cancer. 2007;59(2):258-68
pubmed: 18001220
PLoS One. 2014 Jul 07;9(7):e100314
pubmed: 24999622
Clin Cancer Res. 1996 Apr;2(4):659-68
pubmed: 9816216
Food Chem Toxicol. 2007 Nov;45(11):2179-205
pubmed: 17698276
Drug Metab Rev. 2006;38(4):769-89
pubmed: 17145701
Nat Rev Drug Discov. 2004 Aug;3(8):711-5
pubmed: 15286737
J Appl Biomater Funct Mater. 2018 Jul;16(3):144-150
pubmed: 29609492
Sci Rep. 2016 Apr 12;6:24049
pubmed: 27068577
In Vitro Cell Dev Biol. 1986 Aug;22(8):449-56
pubmed: 3733640
Nutrients. 2015 Apr 02;7(4):2345-58
pubmed: 25849945
EMBO Rep. 2013 Aug;14(8):686-95
pubmed: 23846313
Redox Rep. 2005;10(5):237-45
pubmed: 16354412
Biotechnol J. 2017 Oct;12(10):
pubmed: 28786556
Antioxid Redox Signal. 2010 Dec 1;13(11):1699-712
pubmed: 20486766
J Pharm Bioallied Sci. 2015 Apr;7(Suppl 1):S181-3
pubmed: 26015704
Nature. 2011 Jul 06;475(7354):106-9
pubmed: 21734707
Am J Pathol. 2011 Jul;179(1):487-501
pubmed: 21703426
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Regul Toxicol Pharmacol. 2013 Aug;66(3):279-85
pubmed: 23624349
J Theor Biol. 2018 Dec 7;458:133-147
pubmed: 30145131
Cell Tissue Kinet. 1986 Mar;19(2):205-16
pubmed: 3698078
Free Radic Biol Med. 1999 Jan;26(1-2):107-16
pubmed: 9890646
Cancer Sci. 2018 Apr;109(4):900-911
pubmed: 29450944
Lancet Oncol. 2014 Jan;15(1):e22-32
pubmed: 24384491
J Natl Cancer Inst. 2007 Oct 3;99(19):1441-54
pubmed: 17895480
Oncotarget. 2017 Nov 17;8(64):107423-107440
pubmed: 29296175
Cancer Res. 2008 Feb 1;68(3):946-55
pubmed: 18245498
Cell Biol Int. 2007 Oct;31(10):1245-50
pubmed: 17583542
Anticancer Res. 2012 Jan;32(1):61-71
pubmed: 22213289
J Med Life. 2014 Oct-Dec;7(4):572-6
pubmed: 25713625
Drug Discov Today. 2013 Mar;18(5-6):240-9
pubmed: 23073387
Oncol Lett. 2017 Aug;14(2):1275-1280
pubmed: 28789341
Clin Nutr. 2014 Aug;33(4):718-26
pubmed: 24080313

Auteurs

Harald Hundsberger (H)

Department of Medical and Pharmaceutical Biotechnology, IMC University of Applied Sciences Krems, A-3500 Krems, Austria.
Department of Dermatology, Paracelsus Medical University, A-5020 Salzburg, Austria.

Anna Stierschneider (A)

Department of Medical and Pharmaceutical Biotechnology, IMC University of Applied Sciences Krems, A-3500 Krems, Austria.

Victoria Sarne (V)

Department of Medical and Pharmaceutical Biotechnology, IMC University of Applied Sciences Krems, A-3500 Krems, Austria.

Doris Ripper (D)

Department of Medical and Pharmaceutical Biotechnology, IMC University of Applied Sciences Krems, A-3500 Krems, Austria.

Jasmin Schimon (J)

Department of Medical and Pharmaceutical Biotechnology, IMC University of Applied Sciences Krems, A-3500 Krems, Austria.

Hans Peter Weitzenböck (HP)

Department of Medical and Pharmaceutical Biotechnology, IMC University of Applied Sciences Krems, A-3500 Krems, Austria.

Dominik Schild (D)

Department of Medical and Pharmaceutical Biotechnology, IMC University of Applied Sciences Krems, A-3500 Krems, Austria.

Nico Jacobi (N)

Department Life Sciences, Research Institute for Applied Bioanalytics and Drug Development, IMC University of Applied Sciences Krems, A-3500 Krems, Austria.

Andreas Eger (A)

Department of Medical and Pharmaceutical Biotechnology, IMC University of Applied Sciences Krems, A-3500 Krems, Austria.
Department Life Sciences, Research Institute for Applied Bioanalytics and Drug Development, IMC University of Applied Sciences Krems, A-3500 Krems, Austria.

Josef Atzler (J)

Molecular Devices, LLC, A-5071 Wals-Siezenheim, Austria.

Christian T Klein (CT)

Department of Medical and Pharmaceutical Biotechnology, IMC University of Applied Sciences Krems, A-3500 Krems, Austria.

Christoph Wiesner (C)

Department of Medical and Pharmaceutical Biotechnology, IMC University of Applied Sciences Krems, A-3500 Krems, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH